The Effect on Immunocyte by 22-Oxacalcitriol in the Hemodialysis Patients with Hyperparathyroidism

The hyperparathyroid bone continues to be a major problem in dialysis treatment. A pharmacological parathyroidectomy by 22-oxacalcitriol (OCT), a new vitamin D derivative, is anticipated to be a new and alternative therapeutic modality to conventional oral vitamin D3 pulse therapy. To ensure the clinical viability of this new treatment, we studied the long-term effects of OCT on immunocytes in 7 hemodialysis patients as immunocometence has been acknowledged to be an important factor in survivorship. Counts of CD3, CD4, CD8, CD16, CD20, and CD25 immunocytes were obtained every 6 months over 12 months of treatment. At the start of OCT treatment, counts of CD25 cells were as high as 76±38 /μL, but then decreased to 33±17 /μL at the termination of OCT treatment (p